Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs).
Rutkowski P, Nowecki ZI, Debiec-Rychter M, Grzesiakowska U, Michej W, Woźniak A, Siedlecki JA, Limon J, vel Dobosz AJ, Kakol M, Osuch C, Ruka W. Rutkowski P, et al. Among authors: grzesiakowska u. J Cancer Res Clin Oncol. 2007 Sep;133(9):589-97. doi: 10.1007/s00432-007-0202-4. Epub 2007 Apr 26. J Cancer Res Clin Oncol. 2007. PMID: 17458563
Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor.
Rutkowski P, Nowecki ZI, Michej W, Debiec-Rychter M, Woźniak A, Limon J, Siedlecki J, Grzesiakowska U, Kakol M, Osuch C, Polkowski M, Głuszek S, Zurawski Z, Ruka W. Rutkowski P, et al. Among authors: grzesiakowska u. Ann Surg Oncol. 2007 Jul;14(7):2018-27. doi: 10.1245/s10434-007-9377-9. Epub 2007 May 2. Ann Surg Oncol. 2007. PMID: 17473953
Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors.
Rutkowski P, Debiec-Rychter M, Nowecki ZI, Wozniak A, Michej W, Limon J, Siedlecki JA, Jerzak Vel Dobosz A, Grzesiakowska U, Nasierowska-Guttmejer A, Sygut J, Nyckowski P, Krawczyk M, Ruka W. Rutkowski P, et al. Among authors: grzesiakowska u. Med Sci Monit. 2007 Nov;13(11):CR515-522. Med Sci Monit. 2007. PMID: 17968300
The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.
Rutkowski P, Bylina E, Klimczak A, Switaj T, Falkowski S, Kroc J, Lugowska I, Brzeskwiniewicz M, Melerowicz W, Osuch C, Mierzejewska E, Wasielewski K, Woźniak A, Grzesiakowska U, Nowecki ZI, Siedlecki JA, Limon J. Rutkowski P, et al. Among authors: grzesiakowska u. BMC Cancer. 2012 Mar 22;12:107. doi: 10.1186/1471-2407-12-107. BMC Cancer. 2012. PMID: 22439647 Free PMC article.
What are the current outcomes of advanced gastrointestinal stromal tumors: who are the long-term survivors treated initially with imatinib?
Rutkowski P, Andrzejuk J, Bylina E, Osuch C, Switaj T, Jerzak vel Dobosz A, Grzesiakowska U, Jurkowska M, Woźniak A, Limon J, Dębiec-Rychter M, Siedlecki JA. Rutkowski P, et al. Among authors: grzesiakowska u. Med Oncol. 2013 Dec;30(4):765. doi: 10.1007/s12032-013-0765-7. Epub 2013 Nov 12. Med Oncol. 2013. PMID: 24217870 Free PMC article.
18 results